IS6678A - Hvarfefni og prófanir fyrir ß-sekretasavirkni - Google Patents

Hvarfefni og prófanir fyrir ß-sekretasavirkni

Info

Publication number
IS6678A
IS6678A IS6678A IS6678A IS6678A IS 6678 A IS6678 A IS 6678A IS 6678 A IS6678 A IS 6678A IS 6678 A IS6678 A IS 6678A IS 6678 A IS6678 A IS 6678A
Authority
IS
Iceland
Prior art keywords
reagents
tests
secretory activity
substrates
asp
Prior art date
Application number
IS6678A
Other languages
English (en)
Inventor
Yan Riqian
G. Tomasselli Alfredo
E. Gurney Mark
L. Emmons Thomas
Jerome Bienkowski Michael
L. Heinrikson Robert
Original Assignee
Pharmacia & Upjohn Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Company filed Critical Pharmacia & Upjohn Company
Publication of IS6678A publication Critical patent/IS6678A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS6678A 2000-07-19 2003-01-14 Hvarfefni og prófanir fyrir ß-sekretasavirkni IS6678A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21979500P 2000-07-19 2000-07-19
US27525101P 2001-03-12 2001-03-12
PCT/US2001/023035 WO2002006306A2 (en) 2000-07-19 2001-07-19 SUBSTRATES AND ASSAYS FOR β-SECRETASE ACTIVITY

Publications (1)

Publication Number Publication Date
IS6678A true IS6678A (is) 2003-01-14

Family

ID=26914256

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6678A IS6678A (is) 2000-07-19 2003-01-14 Hvarfefni og prófanir fyrir ß-sekretasavirkni

Country Status (11)

Country Link
US (8) US7205120B2 (is)
EP (1) EP1301604B1 (is)
JP (1) JP2004504018A (is)
AT (1) ATE397077T1 (is)
AU (1) AU2001277950A1 (is)
CA (1) CA2410898A1 (is)
DE (1) DE60134230D1 (is)
IL (1) IL153943A0 (is)
IS (1) IS6678A (is)
TW (2) TW200628612A (is)
WO (1) WO2002006306A2 (is)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1161769C (zh) 1998-04-06 2004-08-11 伊美申公司 数据存储盘的反转光学母盘的制造
US7196163B2 (en) 2001-05-22 2007-03-27 Merk & Co., Inc. Assays using amyloid precursor proteins with modified β-secretase cleavage sites to monitor β-secretase activity
TWI243826B (en) * 2001-07-19 2005-11-21 Akzo Nobel Nv Process for the preparation of peptides
TWI247012B (en) * 2001-07-19 2006-01-11 Akzo Nobel Nv Process for rapid solution synthesis of peptides
CA2482824A1 (en) * 2002-04-18 2003-10-23 Esbatech Ag Method for the identification of modulators of a secretase activity
JP2004000060A (ja) * 2002-05-31 2004-01-08 Otsuka Pharmaceut Co Ltd アミロイドβ産生に影響を与える化合物のスクリーニング方法
WO2004046687A2 (en) * 2002-11-14 2004-06-03 Qtl Biosystems, Llc Methods of biosensing using fluorescent polymers and quencher-tether-ligand bioconjugates
US20050112696A1 (en) * 2003-11-25 2005-05-26 The University Of Texas Southwestern Medical Center Compositions, methods and assays related to secretase cleavage specificity
US20060098887A1 (en) * 2004-05-19 2006-05-11 Hazem El-Bakry Mehthod for image conversion
MX2007011234A (es) * 2005-03-14 2007-11-12 Transtech Pharma Inc Derivados de benzazol, composiciones y metodos de uso en la forma de inhibidores de b-secretasa.
DE102005051978A1 (de) * 2005-10-31 2007-05-10 Forschungszentrum Borstel Zentrum für Medizin und Biowissenschaften Verfahren zur Bestimmung der Spaltbarkeit von Substraten
JP4848986B2 (ja) * 2007-03-22 2011-12-28 富士ゼロックス株式会社 光導波路及びその製造方法
US8548257B2 (en) * 2009-01-05 2013-10-01 Apple Inc. Distinguishing between faces and non-faces
TW201300417A (zh) 2010-11-10 2013-01-01 Genentech Inc 用於神經疾病免疫療法之方法及組合物
JP2013158281A (ja) * 2012-02-03 2013-08-19 Shionogi & Co Ltd 新規ｂａｃｅ１活性測定方法
CN107108745B (zh) 2014-11-19 2021-01-12 基因泰克公司 抗bace1的抗体和其用于神经疾病免疫疗法的用途
WO2016081640A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
US20220389400A1 (en) * 2019-11-08 2022-12-08 Gwangju Institute Of Science And Technology Synthetic alpha-secretase and use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292652A (en) 1990-10-05 1994-03-08 Athena Neurosciences, Inc. Amyloidin protease and uses thereof
US5798224A (en) * 1992-12-29 1998-08-25 Doheny Eye Institute Nucleic acids encoding protocadherin
JP4052605B2 (ja) * 1994-05-18 2008-02-27 タカラバイオ株式会社 α−１，３／４−フコシダーゼ遺伝子
AU6383396A (en) * 1995-06-07 1996-12-30 Athena Neurosciences, Inc. Beta-secretase, antibodies to beta-secretase, and assays for detecting beta-secretase inhibition
US6803188B1 (en) * 1996-01-31 2004-10-12 The Regents Of The University Of California Tandem fluorescent protein constructs
GB9701684D0 (en) 1997-01-28 1997-03-19 Smithkline Beecham Plc Novel compounds
WO1999040930A1 (en) * 1998-02-12 1999-08-19 Center For Blood Research, Inc. Specific inhibitors of nfat activation by calcineurin and their use in treating immune-related diseases
US7090976B2 (en) * 1999-11-10 2006-08-15 Rigel Pharmaceuticals, Inc. Methods and compositions comprising Renilla GFP
EP1084240A1 (fr) * 1998-06-05 2001-03-21 Aventis Pharma S.A. Polypeptides possedant une activite de type beta-secretase
DE69920473T2 (de) * 1998-07-21 2006-02-23 Cytovia, Inc., San Diego Neue fluoreszenzfarbstoffe und ihre anwendung in fluoreszenznachweisverfahren ganzer zellen für kaspasen, peptidasen, proteasen und andere enzyme sowie deren verwendung
KR20070013361A (ko) 1998-09-24 2007-01-30 파마시아 앤드 업존 캄파니 엘엘씨 알츠하이머병 세크레타제
US6313268B1 (en) * 1998-10-16 2001-11-06 Vivian Y. H. Hook Secretases related to Alzheimer's dementia
JP4653318B2 (ja) 1999-02-10 2011-03-16 エラン ファーマシューティカルズ，インコーポレイテッド βセクレターゼ酵素組成物および方法
WO2000058479A1 (en) 1999-03-26 2000-10-05 Amgen Inc. Beta secretase genes and polypeptides
CA2374346C (en) * 1999-06-28 2010-06-22 Jordan J. N. Tang Inhibitors of memapsin 2 and use thereof
US7429639B2 (en) * 1999-09-29 2008-09-30 Ludwig Institute For Cancer Research SSX-2 peptides presented by HLA class II molecules
GB9925136D0 (en) * 1999-10-22 1999-12-22 Smithkline Beecham Plc Novel treatment
CN101935352A (zh) * 1999-12-08 2011-01-05 智力神经系统学公司 作为免疫原的嵌合肽及其抗体,以及利用嵌合肽或抗体进行免疫的方法
JP2003528071A (ja) * 2000-03-23 2003-09-24 エラン ファーマスーティカルズ インコーポレイテッド アルツハイマー病治療用組成物および方法
US20030096864A1 (en) * 2000-06-30 2003-05-22 Fang Lawrence Y. Compounds to treat alzheimer's disease
CA2448142A1 (en) 2001-05-22 2002-11-28 Merck & Co., Inc. Beta-secretase substrates and uses thereof

Also Published As

Publication number Publication date
WO2002006306A2 (en) 2002-01-24
JP2004504018A (ja) 2004-02-12
WO2002006306A3 (en) 2002-07-25
US7888291B2 (en) 2011-02-15
US7205120B2 (en) 2007-04-17
ATE397077T1 (de) 2008-06-15
IL153943A0 (en) 2003-07-31
US20040254342A1 (en) 2004-12-16
TWI316960B (en) 2009-11-11
US20040241792A1 (en) 2004-12-02
CA2410898A1 (en) 2002-01-24
US20040254341A1 (en) 2004-12-16
US20080299596A1 (en) 2008-12-04
EP1301604A2 (en) 2003-04-16
TW200628612A (en) 2006-08-16
AU2001277950A1 (en) 2002-01-30
US20080090260A1 (en) 2008-04-17
US20050096457A1 (en) 2005-05-05
EP1301604B1 (en) 2008-05-28
US20030017991A1 (en) 2003-01-23
US20040253706A1 (en) 2004-12-16
US7803739B2 (en) 2010-09-28
DE60134230D1 (de) 2008-07-10

Similar Documents

Publication Publication Date Title
IL153943A0 (en) SUBSTRATES AND ASSAYS FOR beta-SECRETASE ACTIVITY
DE60144145D1 (de) Subtilisin-variante
DE60325892D1 (de) Stellungs- und verwendungsverfahren
ATE380822T1 (de) Funf-helix protein
ATE496123T1 (de) Nukleinsäuren, welche für tramsmembran serin proteasen kodieren, die kodierten proteine und darauf basierende methoden
DK1229047T3 (da) IL-1-receptor-fusionsproteiner anvendt som antagonister og fremgangsmåder til fremstilling og anvendelse
WO2003031464A3 (en) Remodeling and glycoconjugation of peptides
NZ521396A (en) Fusion proteins comprising two or more Neisseria polypeptides
DK1149905T3 (da) Fremgangsmåder og præparat til polypeptidteknologi
DK1084146T3 (da) Hybridprotein til inhibering af degranuleringen af mastocyter og anvendelse deraf
ATE382148T1 (de) Antikörper für apoptosemarker und anwendungsverfahren
ATE350470T1 (de) Durch thrombin spaltbare chimäre proteine
DK1532261T3 (da) Fremgangsmåder og DNA-konstrukter til produktion af polypeptider med højt udbytte
DK372086D0 (da) Fremgangsmaade til rekombinant-dna-syntese af en serinproteaseinhibitor og dna-sekvenser, som er nyttige derved
DE602005026855D1 (de) Vorrichtungen und verfahren zur bestimmung von proteaseaktivität
ATE323763T1 (de) Dna & protein bindende miniatur proteine
EA200400392A1 (ru) Связывающий каспазу-8 белок, его получение и применение
ATE385805T1 (de) Neue peptide
DE60316718D1 (de) Lösliche notch basierte substrate für gamma secretase, methoden, zusammensetzungen und verwendungen davon
WO2000068416A3 (de) Methoden zur auffindung von proteasen, die spezifisch membrangebundene substrate spalten
DK0994187T3 (da) Renin-aktivt stof omfattende humant prorenin og antistoffer mod prorenin-profragmentet
DE60229043D1 (de) Rearrangierte plattenepithelkarzinomantigen-gene ii
MXPA02012030A (es) Sustratos peptidicos de metalorpoteasas y metodos.
GB0221169D0 (en) Crystal
SE0101519D0 (sv) Nucleic ACID